nectin-4 x Tubulin

Quan Capital and Partners Investment among new investors joining the Series A+ financing round led by Eight Roads Additional $13 Million extends runway into 2025 and helps to accelerate development of portfolio programs SAN DIEGO and SHANGHAI, Dec. 5, 2023 /PRNewswire/ -- Adcentrx Therapeutics ("Adcentrx"), a biotechnology company dedicated to revolutionizing Antibody-Drug Conjugate (ADC) therapeutics for cancer and other life-threatening diseases, today announced the extension of its Series A+ financing. The additional $13 million adds to the $38 million Series A+ round that was closed in April 2023. The Series A+ extension included participation from Quan Capital and Partners Investment. "We are pleased to announce the extension of our Series A+ financing round," said Hui Li, Ph.D., Founder and CEO of Adcentrx. "With the backing of our new investors, we are better positioned to accelerate the clinical development of our lead program, ADRX-0706, and progression of additional pipeline programs towards the clinic. This allows us to continue our mission of creating differentiated therapeutics to address cancer and other life-threatening diseases." Lighthouse Capital acted as Adcentrx's financial advisor. The additional proceeds will be used by Adcentrx to continue advancing its propriety ADC therapeutic pipeline in the clinic. About ADRX-0706 ADRX-0706 is an ADC product candidate discovered by Adcentrx. The antibody component targets Nectin-4, a cell surface adhesion protein over-expressed in multiple human cancers and associated with poor disease prognosis. The ADC is produced using Adcentrx's proprietary i-Conjugation™ technology and novel tubulin inhibitor payload, AP052, to generate an ADC with a drug-antibody ratio of eight (DAR 8). ADRX-0706 has a favorable pharmacokinetic and safety profile in preclinical models, and has demonstrated significant efficacy across a variety of tumor indications. ADRX-0706 is currently being evaluated in a Phase 1a/b clinical trial. For more information about the trial, please refer to the Study ID NCT06036121 on ClinicalTrials.gov. About Adcentrx Therapeutics Adcentrx is a biotechnology company focused on accelerating breakthroughs in protein conjugate therapeutic development for cancer and other life-threatening diseases. By combining the targeting precision of biologics and the disease fighting power of small molecule payloads, Adcentrx strives to develop next-generation targeted therapies for improving patient treatment options. Adcentrx has pioneered the development of an ADC technology toolbox addressing key components of protein conjugate design to solve challenges typically seen in ADCs. For more information about Adcentrx and its innovative ADC technologies, please visit . About Quan Capital Quan Capital is a life sciences venture capital firm with strong China expertise and global capabilities. The firm discovers, incubates and grows next-generation life science companies in early and growth stage, worldwide. Quan's portfolio companies pioneer differentiated therapies and enabling technologies to address major human diseases with high unmet medical needs. Quan has offices in Shanghai and Palo Alto. The firm's investment professionals combine their strong expertise in both science and business with their diverse experiences in global drug development and healthcare investments, and they leverage their broad network worldwide to help maximize the company's value across geographies and development stages. Visit to learn more. About Partners Investment Partners Investment is a Seoul-based venture capital firm founded in 2000 investing in breakthrough technologies in healthcare and therapeutics globally. With cumulative $1 billion in assets under management, the firm is currently managing more than 50 portfolio companies in the US, China, Europe and Korea. Partners Investment was built upon the belief that the demand for improved health will always be paramount and that investing in healthcare innovations will benefit patients with unmet medical needs. For more information about Partners Investment, please visit Contact Information: Investor Relations [email protected] SOURCE Adcentrx Therapeutics

SAN DIEGO, Sept. 27, 2023 /PRNewswire/ -- Adcentrx Therapeutics Inc. ("Adcentrx"), a biotechnology company dedicated to revolutionizing Antibody-Drug Conjugate (ADC) therapeutics for cancer and other life-threatening diseases, today announced the first patient dosed in the Phase 1a/b study of ADRX-0706 for the treatment of advanced solid tumors. "We are pleased to announce this important milestone for Adcentrx that marks our transition from the discovery stage into a clinical stage company," said Hui Li, Ph.D., Founder and Chief Executive Officer of Adcentrx. "We are enthusiastic about the potential of ADRX-0706 to address the unmet needs of patients with Nectin-4 expressing cancers." The first-in-human Phase 1a/b clinical trial of ADRX-0706 is an open-label, multicenter dose escalation and dose expansion study. The study is enrolling patients with select advanced solid tumors. The primary objectives of the study are to characterize the safety and tolerability and to determine the optimal dose of ADRX-0706. The company expects an initial data readout in the middle of 2024. About ADRX-0706 ADRX-0706 is an ADC product candidate discovered by Adcentrx. The antibody component targets Nectin-4, a cell surface adhesion protein over-expressed in multiple human cancers and associated with poor disease prognosis. The ADC is produced using Adcentrx's proprietary i-Conjugation™ technology and novel tubulin inhibitor payload, AP052, to generate an ADC with a drug-antibody ratio of eight (DAR 8). ADRX-0706 has a favorable pharmacokinetic and safety pro preclinical models, and has demonstrated significant efficacy across a variety of tumor indications. About Adcentrx Therapeutics Adcentrx is a biotechnology company focused on accelerating breakthroughs in protein conjugate therapeutic development for cancer and other life-threatening diseases. Adcentrx has pioneered the development of an ADC technology platform addressing key components of protein conjugate design to solve challenges typically seen in ADCs. In addition to the lead candidate, ADRX-0706, Adcentrx is developing a robust pipeline of potential first-in-class and best-in-class candidates. For more information about Adcentrx and its innovative ADC technologies, please visit . For more information about the ADRX-0706 Phase 1a/b clinical trial, please refer to the Study ID NCT06036121 on ClinicalTrials.gov. Contact Information: Investor Relations [email protected]

First asset utilizing Adcentrx's ADC platform to receive IND clearance Planned Phase 1a/1b clinical trial expected to begin in 2H 2023 SAN DIEGO, July 17, 2023 /PRNewswire/ -- Adcentrx Therapeutics Inc. ("Adcentrx"), a biotechnology company dedicated to revolutionizing Antibody-Drug Conjugate (ADC) therapeutics for cancer and other life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application of ADRX-0706 for the treatment of select advanced solid tumors. "The FDA's acceptance of our IND application is an exciting milestone for Adcentrx," said Hui Li, Ph.D., Founder and Chief Executive Officer of Adcentrx. "As our first program to receive FDA clearance, we are one step closer to bringing our novel ADC technology to patients in need across the oncology landscape." Nectin-4 is an attractive target for ADCs due to its high expression in multiple solid tumors and limited expression in normal tissues. It plays a crucial role in tumor progression and has been associated with poor prognosis and resistance to conventional therapies. By specifically targeting Nectin-4 with ADRX-0706, potent anti-cancer activity can be achieved with a lower toxicity profile, offering a promising alternative over current therapeutic approaches. "ADRX-0706 demonstrated a remarkable efficacy and safety pro preclinical studies," added Pia Challita-Eid, Ph.D., Chief Scientific Officer of Adcentrx. "We are thrilled to be progressing our first program into the clinic as we continue to apply our optimized ADC platform on a robust and differentiated product pipeline." The first-in-human Phase 1a/1b clinical trial of ADRX-0706 will be an open-label, multicenter, non-randomized dose escalation and dose expansion study. The study will enroll patients with select advanced solid tumors. The primary objectives of the study will be to characterize the safety and tolerability and to determine the optimal dose of ADRX-0706. The company expects the first patient to be enrolled in the second half of 2023, with an initial data readout in the middle of 2024. About ADRX-0706 ADRX-0706 is an ADC product candidate discovered by Adcentrx. The antibody component targets Nectin-4, a cell surface adhesion protein over-expressed in multiple human cancers and associated with poor disease prognosis. The ADC is manufactured using a proprietary conjugation technology and novel tubulin inhibitor payload to generate an ADC with a drug-antibody ratio of eight (DAR 8). ADRX-0706 has demonstrated a favorable pharmacokinetic and safety pro preclinical models, in addition to demonstrating significant efficacy across a variety of tumor indications. About Adcentrx Therapeutics